that need further strengthening and/or clarifications. For instance, referee 1 suggests extending the statistical analysis to support the methodological assumptions on which the study is based. S/he also asks why only very few known host-pathogens interactors were identified. Reviewer 2 calls for independent cross-validation of the prediction method to support the general applicability of the method and referee 3 points out a number of aspects that require further clarifications and additional information currently not found in the paper. Given these positive evaluations, the reviewers constructive comments and the potential interest of the study, I would like to give you the opportunity to revise your manuscript, with the understanding
Thank you very much for the submission of your research manuscript to our editorial office. Please accept my apologies for the unusual delay in the review process. We have now received the full set of reviews on your manuscript.
You will see that all reviewers appreciate the interest of your study and support publication of the manuscript in our journal. However, they also pinpoint certain aspects of your analysis that need further strengthening and/or clarifications. For instance, referee 1 suggests extending the statistical analysis to support the methodological assumptions on which the study is based. S/he also asks why only very few known host-pathogens interactors were identified. Reviewer 2 calls for independent cross-validation of the prediction method to support the general applicability of the method and referee 3 points out a number of aspects that require further clarifications and additional information currently not found in the paper. Given these positive evaluations, the reviewers constructive comments and the potential interest of the study, I would like to give you the opportunity to revise your manuscript, with the understanding that the main concerns of the reviewers should be addressed. Acceptance of the manuscript will depend on a positive outcome of a second round of review and I should also remind you that it is EMBO reports policy to allow a single round of revision only and that therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript.
Revised manuscripts should be submitted within three months of a request for revision; they will otherwise be treated as new submissions. If you feel that this period is insufficient for a successful submission of your revised manuscript I can potentially extend this period slightly. Also, the length of the revised manuscript should not exceed roughly 29,000 characters (including spaces and references). If you feel that the additional data requested by the reviewers would make the manuscript too long you may consider including some peripheral data in the form of Supplementary information. However, materials and methods essential for the repetition of the key experiments should be described in the main body of the text and may not be displayed as supplemental information only.
When submitting your revised manuscript, please include:
• a word-formatted version of the manuscript text • editable, high-resolution TIFF or EPS-formatted or figure files • a separate single PDF file of all the Supplementary information (in its final format)
• a letter detailing your responses to the referee comments (as word file if possible) • a short, two-sentence summary of the manuscript As part of the EMBO publication's Transparent Editorial Process, EMBO reports publishes online a Review Process File to accompany accepted manuscripts. This File will be published in conjunction with your paper and will include the referee reports, your point-by-point response and all pertinent correspondence relating to the manuscript.
You are able to opt out of this by letting the editorial office know (emboreports@embo.org). If you do opt out, the Review Process File link will point to the following statement: "No Review Process File is available with this article, as the authors have chosen not to make the review process public in this case."
We also welcome the submission of cover suggestions or motifs that might be used by our Graphics Illustrator in designing a cover.
I look forward to seeing a revised form of your manuscript when it is ready. Should you in the meantime have any questions, please do not hesitate to contact me.
REFEREE REPORTS:
Referee #1:
An interesting in silico method is described for identifying virus-host interactions. The experimental validation of the method is impressive with essentially all the predicted interactors above a particular score threshold being being experimentally validated as binding to the bait protein NS1. This performance is a bit surprising given the unsupported assumption on which the method is based: that structural homologs are enriched in interactions with the same protein. One could consider for example antibodies, which are structurally homologous but bind to very different proteins/epitopes, albeit by natural design. Using the SCOP database and the PPI interaction database, the authors could certainly generate general statistics to support their fundamental methodological assumption. This may be important in convincing readers that the method is not specific to NS1 and influenza used on the VirHost DB.
Secondly, it is a little bit surprising in Figure 4 that only three protein interactions out of many are BOTH identified in the literature and predicted by this method. A priori, one measure of the accuracy of this method would be its ability to retrieve interactions predicted in the literature, and I would only expect little overlap if the number of true interactions were much greater than the number reported in the literature (and the method accurately predicted the true interactions). The authors should offer a plausible explanation for this puzzling distribution.
Overall, however, it is hard to be too skeptical when the experimental validation data is so strong. One possible bias is that the 32 proteins tested were selected based on their availability in ORFeome. This sounds suitably random, but just in case, the authors should describe what percentage of the human genome is available in ORFeome and provide some other discussion of its contents to ensure that the reader is convinced that the 32 selected for experimental testing were semi-randomly selected.
None of the above are fatal flaws. The figures are clear. The story is concise. Referee #2:
de Chassey et al. developed a new method to predict viral-host protein-protein interactions by examining interactors of structurally homologous proteins of the influenza NS1 protein. 69 interactors were predicted and 32 of these were verified by either Y2H and/or GST pull-down. Having experimentally validated their method, the authors then proceeded to perform a genomewide prediction and generated an interactome map of 108 interactions connecting 41 cellular proteins to 6 viral proteins. The manuscript is clearly written and easy to follow. The experimental verifications are quite extensive.
My main concern, however, is that the author should perform rigorous cross-validation evaluation of the prediction method and the tuning of its parameters, especially because the title implies that this new method is generally applicable to predict viral-host interactions for different viruses. Just to be clear, I agree with the assumption of the authors (structurally homologous proteins are more likely to share interactors) and think that their method will likely to perform well. Nevertheless, this should be thoroughly assessed using ROC, Precision-Recall, etc, which in my opinion will significantly improve the profile of the paper. Furthermore, other labs have proposed similar approaches to use structural information to predict protein-protein interactions within species (such as PRISM, Nature Protocols 6, 1341-1354). The authors should at least cite these publications.
I also like the rigor the authors exercised to select only high confidence human interactions. However, I do believe the authors should cite previous publications discussing low-confidence interactions polluting the databases (e.g. Cusick et al. Nature Methods, 6: 39-46). Furthermore, another important aspect of protein interactions is whether two proteins interact directly (binary) or are simply involved in the same complex (co-complex association). For the authors' method to work, I think only binary interactions should be included. In fact, the HINT database (http://hint.yulab.org/) provides all of these types of information (including high vs. low confidence, binary vs. co-complex, and low-throughput vs. high-throughput). The author should use the highconfidence low-throughput binary data from HINT for their method.
Referee #3:
Rationale The paper describes a approach to predict virus-human interactions. It is based on finding structural homologs of the viral protein (viral or human) and mapping the interaction partners of these homologs (from a high-confidence database). A score is defined for each candidate protein interaction that favors proteins that are independently identified from multiple structural homologs. A high performance predictor of HP-PPI would greatly aid current research in infection.
The original aspect of this approach is to take structural homologs and calculate a cumulative score for independent interactions. The score therefore should roughly represent conservation of the interaction ("structural interologs").
Major concerns: -page 3: NS1 structural homologs with a Dali z-score between 2 and 20 were retained to include weakly homologous proteins and exclude fully homologous NS1 proteins . Hence, known NS1-human interactors were not favored.
-The PDB file of NS1 were they start with is 3F5T (page 5, material and methods). This is fed to a standalone version of DALI (the web version gives the following results http://ekhidna.biocenter.helsinki.fi/dali_server/results/20130306-0109-0874ade106bae2a9867ed91d220877ad/index.html, this query also contains entries other than human and virus). The scores between 2 and 20 are retained. In the case of viral proteins, this represents more the retaining of parts of the protein (the RNA-binding domain of NS1) than distant NS1 homologs. The RNA-binding part of NS1 occurs redundantly in the PDB, so this selection criteria will give following problems: -It does not exclude multiple reporting of known NS1 interactions -It does favor known NS1 RNA-binding domain interactions (it is mentioned that 58 of the 69 predicted interactions are from this region) -It does not only favor distant homologs of NS1 but also parts of close homologs Therefore, unless all the entries were checked to exclude this (this information should be available for a thorough review), we cannot address the redundancy in the reporting that will create a bias in the score.
It looks from the web-based DALI results that there is (between 2 and 20) only 1 effector domain (a real distant?), that the RBD of related strains is selected for viral homologs (these exists of 3 helices), and human domains that consist of 2 helices under a slight angle. The structural information content of human homologs therefore seems to be low (what is the chance of seeing this domain randomly?). Again, more information is needed (besides the range of the DALI score) to asses the quality of the initial query data.
-The method is described very briefly and is as it is not reproducible. Is the VirHostNet database still accessible to query (http://pbildb1.univ-lyon1.fr/virhostnet)? If not, it should be added to the supplementary information.
Score definition (page 5):
"First, an interactor is more confident when predicted by several independent NS1 homologs." Why? As said, most of them are the RBD. The PDB structures are annotated by blasting them against GenBank. This database contains thousands of sequences from Influenza strains that are only slightly different and the database is therefore highly redundant. This inflates predictions unless the authors have manually selected relevant homologs that are sufficiently different (e.g. less then 90%), or if they annotate against a less redundant database. "Interactors independently predicted from both viral and human homologs are favored." This selection criterium probably favors clear examples of horizontal gene transfer if the structural overlap is high. It is probably more reliable if overlap is low (convergent evolution or large evolutionary distances). In this case, structural overlap is probably too low. From searching structural homologs of a RBD helix-turn-helix motif (1LT1 http://ekhidna.biocenter.helsinki.fi/dali_server/results/20130306-0189-7f5862aa7f4d93f1c1c17dce22f1fca7/index.html), it seems that this structural motif is used in protein domains that make contact with RNA or DNA. Most proteins are modular structured (as is NS1) and selection for alike modules does not give reliable information on protein-protein interactions by other part of the protein. The reviewer therefore asks (him/her)self if the method should be applied only to whole proteins or domains that are involved in protein-protein interactions. The method will otherwise result in meaningless results.
-Y2H page 6: I assume that the full length ORFs for the GST pull-down assays were also cloned and used in the Y2H assay. Many of the proteins that give positive results in the Y2H assay are associated with the cell membrane or mitochondrial membrane (IL10RA, UCP3, B2L11, BAD). IL10RA is a single-pas transmembrane receptor and an interaction with a cytosolic protein can only be detected by a modified version of Y2H, like MYTH. There is no Y2H evidence for this protein to the reviewers knowledge. The same is true for UCP3 which is an integral membrane protein in the mitochondrion. In this case the Y2H of UCP3 (PMID 10785390) was performed on hydrophilic loops of UCP3. Did the authors take this into account? Otherwise the results are very strange.
-Impact of silencing NS1 interactors on influenza A virus replication Using this criteria and after exclusion of toxic siRNAs, 10 new cellular interactors of NS1 were found to directly modulate the replication of influenza A virus -3 were functioning as restriction host factors and 7 as essential host factors (Figs 2A,C,D). Therefore, the method generated a dataset that is strongly enriched in modulators of replication-43.5 % vs 0.05 to 1.2 % for siRNA pangenomic screens. The term modulators of viral replication is unfortunate. How can the authors claim that they regulate viral replication without addressing the fact that RNAi knockdown of e.g. TAF1 or the proteins in the apoptotic pathway affect cell survival and can cause the effect on viral replication indirectly?
CONCLUSION: the reviewers are skeptical about the methods and results in this paper. Additional information is required on the wet and dry lab parts (very sparse information which make it difficult to guess what they exactly do) and the major concerns need to be addressed. Referee #1:
We totally agree with the reviewer that general statistics supporting our assumption would strongly reinforce the manuscript. This shows that the assumption "when two proteins are structurally homologs, they are more likely to have interactors in common" is clearly confirmed at each level of the SCOP hierarchy. It is therefore not specific to NS1 and other influenza proteins but a general feature of human and viral proteins.
This analysis is now fully explained in supplementary information and a sentence has been added in the text in the RESULTS AND DISCUSSION, section "Principle of the method": "Using the Structural Classification of Proteins from SCOP database (Murzin et al.) and the high--quality datasets of protein--protein interactions from the VirHostNet database (Navratil et al.), we showed that this assumption is a general feature of human and viral proteins (supplementary information online)."
Secondly, it is a little bit surprising in Figure 4 that only three protein interactions out of many are BOTH identified in the literature and predicted by this method. A priori, one measure of the accuracy of this method would be its ability to retrieve interactions predicted in the literature, and I would only expect little overlap if the number of true interactions were much greater than the number reported in the literature (and the method accurately predicted the true interactions). The authors should offer a plausible explanation for this puzzling distribution. Overall, however, it is hard to be too skeptical when the experimental validation data is so strong. One possible bias is that the 32 proteins tested were selected based on their availability in ORFeome. This sounds suitably random, but just in case, the authors should describe what percentage of the human genome is available in ORFeome and provide some other discussion of its contents to ensure that the reader is convinced that the 32 selected for experimental testing were semi-randomly selected. interactors were predicted and 32 of these were verified by either Y2H and/or GST pull-down. Having experimentally validated their method, the authors then proceeded to perform a genomewide prediction and generated an interactome map of 108 interactions connecting 41 cellular proteins to 6 viral proteins. The manuscript is clearly written and easy to follow. The experimental verifications are quite extensive.
My main concern, however, is that the author should perform rigorous cross-validation evaluation of the prediction method and the tuning of its parameters, especially because the title implies that this new method is generally applicable to predict viral-host interactions for different viruses. Just to be clear, I agree with the assumption of the authors (structurally homologous proteins are more likely to share interactors) and think that their method will likely to perform well. Nevertheless, this should be thoroughly assessed using ROC, Precision-Recall, etc, which in my opinion will significantly improve the profile of the paper.
We now provide general statistics supporting our assumption (when two proteins are structurally homologs, they are more likely to have interactors in common). Responding to the first question of Reviewer 1, we have demonstrated that this assumption is a general feature of human and viral proteins. Please see response to question 1 of the Reviewer 1 (Response has not been copied not to overload the document).
As requested, the performance of our method has been assessed (R, package RCOR) using full-length NS1 prediction results, for which we have experimental data. We used the following binary contingency We are aware that a real negative interactor may just be an unknown interactor.
Definition of the measures in this evaluation:
--recall = sensitivity = true positive rate = tp/(tp+fn). Represents the fraction of real positive interactors that are predicted positive. This graph shows that the best performance of our method is obtained when using a score cutoff around 3. At this cutoff, the specificity and the precision are 100% and the sensitivity is 45 %.
The low sensitivity is not an issue for our purpose since we do not aim at predicting proteins that do not interact with NS1. In contrast, fixing a score cutoff at 3 allows prediction of highconfidence interactions with the best specificity and precision.
A sentence has been added in text in RESULTS AND DISCUSSION, section "Validation of NS1 interactors": Performance assessment of the prediction method shows that this score threshold leads to an optimal success regarding specificity and precision (supplementary information online)".
This analysis is now fully described in supplementary information.
Furthermore, other labs have proposed similar approaches to use structural information to predict protein-protein interactions within species (such as PRISM, Nature Protocols 6, 1341-1354). The authors should at least cite these publications. Indeed, the use of a highly confident interaction dataset is essential. Cusick et al. reported that protein interaction databases contain a large error rate [7] for many reasons -difficulty of the curation process from long documents, gene name confusion due to shared synonyms for different genes, "educated guess" by curators, and so on. To overcome these low-confidence interactions polluting the databases, we selected a high-confidence human interaction dataset composed of interactions identified by two different methods or in two independent papers.
A sentence has been added in the text in the METHODS, section « High--quality protein--protein interaction data from VirHostNet": "Indeed, the human interactome is an integration of data from several databases, and may be polluted by low--confidence interactions (Cusick et al.)."
Furthermore, another important aspect of protein interactions is whether two proteins interact directly (binary) or are simply involved in the same complex (co-complex association). For the authors' method to work, I think only binary interactions should be included. In fact, the HINT database (http://hint.yulab.org/) provides all of these types of information (including high vs. low confidence, binary vs. co-complex, and low-throughput vs. high-throughput). The author should use the high-confidence low-throughput binary data from HINT for their method. Table 5 of Das and Yu paper [8] .
HINT database defines a list of PSI-MI evidence codes to classify binary interactions and cocomplex associations. This list is available in the Supplementary
From this database, we have downloaded the literature-curated binary interactome corresponding to the request of the reviewer (high-confidence, low-throughput binary data). A glance to this dataset reveals that many interactions are described with a PSI-MI code MI:0492 or MI:0493. Surprisingly, these codes do not belong to the list of codes used to define a binary interaction. MI:0492 stands for "in vitro" and MI:0493 for "in vivo". In our opinion, these descriptions are too generic to establish that the two proteins interact directly. Moreover, the database is described to select only literature-curated interactions that are supported by two or more publications. In reality, several interactions are supported by only one publication.
To overcome these problems, we applied the HINT criteria to the VirHostNet high-quality dataset to define a high-confidence, low-throughput binary dataset. Using VirHostNet is of particular interest because the criteria can be applied to both the human-human protein interaction dataset and the virus-human protein interaction dataset (no virus-human interaction is described in HINT). We therefore defined a new dataset that is 60% smaller than the dataset initially used in the paper (after exclusion of co-complexes and publications describing more than 100 interactions on our high-quality dataset).
We then recomputed the method to identify NS1 interactors. 12 cellular proteins were predicted to interact with NS1 with a score>= 3. Nine of these proteins belong to the initial list of 26 proteins. The 3 remaining predicted interactors do not belong to this list but were initially just under the threshold of 3. Eight out of the twelve predicted interactors have been tested and validated either in GST pull down or Y2H. These results show that our method is robust even to a drastic reduction of the interactome size.
However, there is a reduction in the number of predicted interactors that is in the range of the reduction of the interactome size. As the method is experimentally validated, this means that the interactions excluded from the initial dataset were essential to predict true interactions. This strengthens our initial criteria used to define the working interactome.
Major concerns:
-page 3: NS1 structural homologs with a Dali z-score between 2 and 20 were retained to include weakly homologous proteins and exclude fully homologous NS1 proteins . Hence, known NS1-human interactors were not favored.
We apologize for the lack of information. Indeed, we had automatically excluded homologs with a Dali z-score above 20 because such values correspond to structurally identical proteins according to Dali guidelines. We had also excluded all homologs that are part of or full-length NS1 proteins of influenza A viruses, of any viral strain and with any z-score value. We had thus avoided any bias towards NS1 and its known interactors.
A sentence has been added in the text in the RESULTS AND DISCUSSION, section "Prediction of influenza A virus NS1 protein interactions": "All homologs that are full-length or part of NS1 proteins of influenza A viruses were also excluded."
We also want to point out the difference between Dali server online and the protocol described in our method. We have used a standalone version of the Dali program to perform systematic pairwise comparisons of 3F5TA against every human and viral PDB chain previously collected and identified. Compared to the Dali server online, slightly differences are expected as the set of PDB chains is different and there is no limit in the number of hits.
Again, we are sorry to have missed to explain that we have excluded from the prediction process all the homologs that are part of or full-length NS1 proteins of influenza A viruses, of any viral strain and with any z-score value. This clarifies for the readers the initial query data.
As stated above, a sentence has been added in the text.
The VirHostNet database is still accessible with an updated dataset since the submission of this paper. Nevertheless, we now provide these datasets in supplementary Tables 6 and 7 . Reference to these tables is provided in the text in the METHODS, section "High-quality protein-protein interaction data from VirHostNet".
Score definition (page 5):
"First, an interactor is more confident when predicted by several independent NS1 homologs." Why? As said, most of them are the RBD. The PDB structures are annotated by blasting them against GenBank. This database contains thousands of sequences from Influenza strains that are only slightly different and the database is therefore highly redundant. This inflates predictions unless the authors have manually selected relevant homologs that are sufficiently different (e.g. less then 90%), or if they annotate against a less redundant database.
Again, we are sorry to have missed the explanation that we have excluded from the prediction process all the homologs that are part of or full-length NS1 proteins of influenza A viruses, of any viral strain and with any z-score values.
As stated above, a sentence has been added in the text to clarify this important point. We also wondered whether the method should be applied to whole proteins or domains that are involved in protein-protein interactions. Supplementary Table 1 shows that most of fulllength NS1 protein predicted interactors are also predicted with NS1 RBD. Nevertheless, NS1 RBD does not predict several proteins in the initial list of 69 predicted interactors. Some of the proteins that are only predicted with the full-length structure are experimentally validated (SORBS2, PHB, CFL1, EDF1). Furthermore, supplementary Table 2 shows that the overlap of predicted interactors of full-length NS1 and the RBD is not 100 %. It seems therefore that both domains and full-length proteins are essential to explore the full potential of this method. Domains also provide mapping information for some interactions.
A sentence has been added in the text in the RESULTS AND DISCUSSION, section "Validation of NS1 interactors": "As the overlap of predicted interactors for full--length NS1 and the RBD is not 100 %, both domains and full--length proteins are essential to explore the full potential of this method." -Y2H page 6: I assume that the full length ORFs for the GST pull-down assays were also cloned and used in the Y2H assay. Many of the proteins that give positive results in the Y2H assay are associated with the cell membrane or mitochondrial membrane (IL10RA, UCP3, B2L11, BAD). IL10RA is a single-pas transmembrane receptor and an interaction with a cytosolic protein can only be detected by a modified version of Y2H, like MYTH. There is no Y2H evidence for this protein to the reviewers knowledge. The same is true for UCP3 which is an integral membrane protein in the mitochondrion. In this case the Y2H of UCP3 (PMID 10785390) was performed on hydrophilic loops of UCP3. Did the authors take this into account? Otherwise the results are very strange.
found to directly modulate the replication of influenza A virus -3 were functioning as restriction host factors and 7 as essential host factors (Figs 2A,C,D) . Therefore, the method generated a dataset that is strongly enriched in modulators of replication-43.5 % vs 0.05 to 1.2 % for siRNA pangenomic screens. The term modulators of viral replication is unfortunate. How can the authors claim that they regulate viral replication without addressing the fact that RNAi knockdown of e.g. TAF1 or the proteins in the apoptotic pathway affect cell survival and can cause the effect on viral replication indirectly?
We Thank you for your patience while we have reviewed your revised manuscript. We have now received the reports of referees 1 and 2, who were asked to assess your revised version. Barbara Pauly is currently out of the office and, thus, I am making a decision on your study so as not to unnecessarily delay the process. As you will see from the reports below, both referees are now positive about the publication of your study in EMBO reports. I am therefore writing an 'accept in principle' decision, which means that we will be happy to accept your manuscript for publication once a few minor issues/corrections have been addressed, as follows.
-I have noted that the legends to figures 2C, 2D and supplementary figure 2 do not contain information regarding the number of independent experiments performed, and what is represented by the bar and the error bars. Please include this information in your final version.
-As a standard procedure, we edit the title and abstract of manuscripts to make them more accessible to a general readership. I have slightly modified your abstract as follows, please let us know if you do NOT agree with any of the changes.
"Virus-host interactomes are instrumental to understand global perturbations of cellular functions induced by infection and discover new therapies. The construction of such interactomes is, however, technically challenging and time-consuming. Here we describe an original method for the prediction of high-confidence interactions between viral and human proteins through a combination of structure and high-quality interactome data. Validation was performed for the NS1 protein of the influenza virus, which led to the identification of new host factors that control viral replication."
-Lastly, we now encourage the publication of original source data -particularly for electrophoretic gels and blots, but also for graphs-with the aim of making primary data more accessible and transparent to the reader. If you agree, you would need to provide one PDF file per figure that contains the original, uncropped and unprocessed scans of all or key gels used in the figures and an Excel sheet or similar with the data behind the graphs. The files should be labeled with the appropriate figure/panel number, and the gels should have molecular weight markers; further annotation could be useful but is not essential. The source files will be published online with the article as supplementary "Source Data" files and should be uploaded when you submit your final version. If you have any questions regarding this please contact me.
After all remaining corrections have been attended to, you will receive an official decision letter from the journal accepting your manuscript for publication in the next available issue of EMBO reports. This letter will also include details of the further steps you need to take for the prompt inclusion of your manuscript in our next available issue.
Thank you for your contribution to EMBO reports.
REFEREE REPORTS:
